v3.26.1
SEGMENT INFORMATION
 6 Months Ended
Apr. 30, 2026
Accounting Policies [Abstract]  
SEGMENT INFORMATION

NOTE 14 – SEGMENT INFORMATION

 

Under ASC 280, Segment Reporting, operating segments are defined as components of an enterprise where discrete financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one reportable and operating segment. The measure of segment assets is reported on the balance sheet as total assets.

 

The Company’s Chief Executive Officer, who is also the CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance.

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM for the three months and six months ended April 30, 2026 and 2025.

 

                               
    Three Months Ended
April 30,		     Six Months Ended
April 30,		  
    2026     2025     2026     2025  
Revenue   $ 2,581,000       1,149,000     $ 4,027,000     $ 2,239,000  
Cost of goods sold     (526,000 )     (256,000 )     (807,000 )     (447,000 )
Salaries & consulting fees     (839,000 )     (716,000 )     (1,562,000 )     (1,425,000 )
Professional fees     (295,000 )     (137,000 )     (455,000 )     (283,000 )
Commissions     (279,000 )     (91,000 )     (465,000 )     (178,000 )
Marketing     (238,000 )     (73,000 )     (342,000 )     (114,000 )
Stock based compensation     (590,000 )     (1,096,000 )     (1,182,000 )     (2,187,000 )
Lab expenses     (204,000 )     (39,000 )     (373,000 )     (41,000 )
Research & development     (31,000 )     (42,000 )     (50,000 )     (48,000 )
Insurance     (47,000 )     (80,000 )     (109,000 )     (106,000 )
Office expenses & other     (45,000 )     (13,000 )     (72,000 )     (57,000 )
Other income (expenses), net     (22,000 )     3,000       3,000       13,000  
Gain on sale of Exotropin interests     390,000       -       390,000       -  
Net loss   $ (145,000 )   $ (1,391,000 )   $ (997,000 )   $ (2,634,000 )